Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive and widely used neuromodulation technology. Small sample studies have shown that rTMS treatment can significantly improve the symptoms of Parkinson's disease(PD) and delay the progression of the disease. In order to further explore the effectiveness of rTMS in the treatment of PD and lay the foundation for its clinical promotion, our research team plans to conduct a randomized double-blind controlled study of rTMS in the treatment of PD in multiple centers across the country.

开始日期2024-11-01

申办/合作机构

安徽医科大学

NCT06383247 / Not yet recruitingN/AIIT

A Randomized, Double-blind, Multicenter, Placebo-controlled Trial: the Efficacy of Repetitive Transcranial Magnetic Stimulation With Precision Neuronavigation in Parkinson's Disease

开始日期2024-11-01

申办/合作机构

安徽医科大学

NCT06642454 / RecruitingN/AIIT

A Comparative Open-Label Crossover Study of Respiratory-Gated Versus Non-Respiratory-Gated Transcutaneous Auricular Vagus Nerve Stimulation for the Treatment of Non-Motor Symptoms in Parkinson's Disease

The goal of this clinical trial is to compare the effects of different modes and frequencies of transcutaneous auricular vagus nerve stimulation (taVNS) on non-motor symptoms in people with Parkinson's disease. The main questions it aims to answer are:
Which mode and frequency of taVNS is most effective in improving non-motor symptoms? Are there any side effects or safety concerns with different taVNS frequencies? Researchers will compare three types of taVNS: 25 Hz non-expiratory gated, 25 Hz expiratory gated, and 100 Hz expiratory gated stimulation.
Participants will:
Receive each type of taVNS in three 2-week cycles, with 2-month breaks between cycles Undergo neuropsychological assessments, imaging, eye-tracking, and biological sample collection before and after each cycle.

开始日期2024-10-01

申办/合作机构

安徽医科大学

100 项与安徽医科大学相关的临床结果

登录后查看更多信息

0 项与安徽医科大学相关的专利（医药）

登录后查看更多信息

32,470

项与安徽医科大学相关的文献（医药）

2025-03-01·Biomaterials

Extracellular vesicles-hitchhiking boosts the deep penetration of drugs to amplify anti-tumor efficacy

Article

作者: He, Xiaoyan ; Peng, Rui ; Shan, Guisong ; Qiao, Lei ; Sun, Gengyun ; Li, Yang ; Sun, Qiuting ; Gao, Min ; Zhang, Ruijie ; Zhang, Huiru ; Liu, Mengyu

Developing drug delivery systems capable of achieving deep tumor penetration is a challenging task, yet there is a significant demand for such systems in cancer treatment. Hitchhiking on tumor-derived extracellular vesicles (EVs) represents a promising strategy for enhancing drug penetration into tumors. However, the limited drug assembly on EVs restricts its further application. Here, we present a novel approach to efficiently attach antitumor drugs to EVs using an engineered cell membrane-based vector. This vector includes the AS1411 aptamer for tumor-specific targeting, the vesicular stomatitis virus glycoprotein (VSV-G) for tumor cell membrane fusion, and a photosensitizer as the therapeutic agent while ensuring optimal drug encapsulation and stability. Upon injection, photosensitizers are firstly transferred to the tumor cell membrane and subsequently piggybacked onto EVs with the inherent secretion process. By hitchhiking with EVs, photosensitizers can be transferred layer by layer deep into the solid tumors. The results suggest that this EVs-hitchhiking strategy enables photosensitizers to penetrate deeply into tumor tissue, thereby enhancing the efficacy of phototherapy. This study offers broad application prospects for delivering drugs deeply into tumor tissues.

2025-03-01·Infectious Disease Modelling

Forecasting influenza epidemics in China using transmission dynamic model with absolute humidity

Article

作者: Tao, Fangfang ; Wang, Xiling ; Chen, Yinzi ; Cheng, Jian ; Zhou, Ying ; Chen, Xiaowei

BackgroundAn influenza forecasting system is critical to influenza epidemic preparedness. Low temperature has long been recognized as a condition favoring influenza epidemic, yet it fails to justify the summer influenza peak in tropics/subtropics. Recent studies have suggested that absolute humidity (AH) had a U-shape relationship with influenza survival and transmission across climate zones, indicating that a unified influenza forecasting system could be established for China with various climate conditions.MethodsOur study has generated weekly influenza forecasts by season and type/subtype in northern and southern China from 2011 to 2021, using a forecasting system combining an AH-driven susceptible-infected-recovered-susceptible (SIRS) model and the ensemble adjustment Kalman filter (EAKF). Model performance was assessed by sensitivity and specificity in predicting epidemics, and by accuracies in predicting peak timing and magnitude.ResultsOur forecast system can generally well predict seasonal influenza epidemics (mean sensitivity>87.5%; mean specificity >80%). The average forecast accuracies were 82% and 60% for peak timing and magnitude at 3-6 weeks ahead for northern China, higher than those of 42% and 20% for southern China. The accuracy was generally better when the forecast was made closer to the actual peak time.DiscussionThe established AH-driven forecasting system can generally well predict the occurrence of seasonal influenza epidemics in China.

2025-02-01·Current Cancer Drug Targets

CNDP1 Suppresses the Malignant Behavior of Hepatoma Cell via Restricting PI3K-AKT-mTOR Activation

Article

作者: Zhang, Na ; Wei, Pengjun ; Pan, Linxin ; Du, Youwen ; Fan, Xu ; Xie, Li ; Wei, Shuangbiao ; Zhang, Wenchen ; Qiao, Zhi ; Chen, Xiaoqian

Introduction:Hepatocellular carcinoma (HCC) is a global health problem with increasing morbidity and mortality, and exploring the diagnosis and treatment of HCC at the gene level has be-come a research hotspot in recent years. As the rate-limiting enzyme of carnosine hydrolysis, CNDP1 participates in the progress of many diseases, but its function in HCC has not been fully elucidated.Methods:This study firstly screened differentially expressed genes from the biochip related to HCC by bioinformatic analysis, and CNDP1 was finally selected for in-depth study. Then the bioinformatics analysis results were validated by detecting the expression of CNDP1 in human HCC samples and he-patoma cell lines. Furthermore, the effect of CNDP1 on the malignant behavior of hepatoma cell lines were assessed using MTT colorimetric assay, EdU staining assay, colony formation, wound-healing assay and transwell, and the molecular mechanism was also preliminarily explored.Results:This study found that CNDP1 expression was decreased significantly in human HCC tissues and cell lines, and its overexpression could significantly suppress cell proliferation, migration and in-vasion of hepatoma cell lines. Mechanistically the GeneMANIA database predicted that CNDP1 could interact with various proteins involved in regulating PI3K-AKT-mTOR signaling pathway. Further-more, this study showed that CNDP1 overexpression could effectively inhibit the activation of PI3K-AKT-mTOR signaling pathways, more significantly, inhibition of PI3K-AKT-mTOR signaling path-way could disrupt the anti-cancer effect of CNDP1 on HCC.Conclusion:This study confirm that CNDP1 expression is decreased significantly in HCC, and has potential anti-cancer activity, this discovery provides a cytological basis for further understanding the biological function of CNDP1 and diagnosis and gene therapy of HCC in the future.

项与安徽医科大学相关的新闻（医药）

2024-10-26

·ioncology

ESMO ASIA 2024丨一文了解重要的妇科肿瘤口头报告

点击蓝字关注我们 2024年欧洲肿瘤内科学会亚洲年会（ESMO Asia Congress 2024）将于当地时间12月6日~8日在新加坡召开。ESMO ASIA是亚太地区讨论肿瘤学领域重磅突破的领先平台，近日在官方网站正式公布本次大会的摘要题目及作者信息。肿瘤瞭望小编带您先睹为快，一览妇科肿瘤领域入选优选口头报告（Proffered Paper）和微型口头报告（Mini Oral）的临床研究。 1 口头报告（Proffered Paper）摘要号：372O 英文标题：Balstilimab (bal) alone or with zalifrelimab (zal) treatment for cervical cancer: an open-label, non-comparative, randomised, phase 2 trial 中文标题：Balstilimab单药或Balstilimab+zalifrelimab治疗宫颈癌：一项开放标签、非对照、随机、II期试验讲者：吴令英(中国医学科学院肿瘤医院) 摘要号：373O 英文标题：First-line iparomlimab and tuvonralimab (QL1706) + chemotherapy (chemo) ± bevacizumab (BEV) for recurrent or metastatic cervical cancer (r/mCC): Updated results of the phase II DUBHE-C-204 study 中文标题：艾帕洛利托沃瑞利单抗(Iparomlimab/Tuvonralimab)+化疗±贝伐珠单抗一线治疗复发性或转移性宫颈癌：II期DUBHE-C-204研究的最新结果讲者：王丹波(辽宁省肿瘤医院) 摘要号：374O 英文标题：The burden and trends of gynecological cancers in Asia from 1980 to 2021: A systematic analysis for the Global Burden of Disease Study 2021 中文标题：1980~2021年亚洲妇科癌症负担及趋势：2021年全球疾病负担研究的系统分析讲者：Run Miao (安徽医科大学) 摘要号：375O 英文标题：DIsease burden and treatment pattern of Recurrent or advanced Endometrial Cancer in Korea: a naTIONwide database (DIRECTION) study 中文标题：韩国复发性或晚期子宫内膜癌的疾病负担和治疗模式：全国数据库DIRECTION研究讲者：Hyun-woong Cho (韩国首尔) 2 微型口头报告（Mini Oral）摘要号：376MO 英文标题：The impact of crossover to surgery in the no-surgery group on the survival: a post-hoc analysis of the SOC-1 trial 中文标题：非手术组患者交叉接受手术对生存的影响：SOC-1试验的事后分析讲者：Lina Shen (中国上海) 摘要号：377MO 英文标题：Lymph node dissection before initial treatment for locally advanced cervical cancer: a systematic review and meta-analysis 中文标题：局部晚期宫颈癌初始治疗前的淋巴结清扫：系统评价与荟萃分析讲者：He Zhang (中国医学科学院肿瘤医院) 摘要号：378MO 英文标题：Efficacy and Safety of Disitamab Vedotin in Treatment of HER2 Expressed Advanced or Recurrent Gynecological Cancers 中文标题：Disitamab Vedotin治疗HER2表达的晚期或复发性妇科癌症的疗效和安全性讲者：王东雁(中山大学孙逸仙纪念医院) 摘要号：379MO 英文标题：Homologous recombination deficiency testing in Vietnamese patients with ovarian cancer 中文标题：越南卵巢癌患者同源重组缺陷检测讲者：Nam H. Tran (越南胡志明市) 摘要号：380MO 英文标题：Role of Therapy in the Development of Second Primary Malignancies in Ovarian Cancer Survivors: A SEER Database Analysis 中文标题：治疗在卵巢癌幸存者中对于发生第二原发性恶性肿瘤的作用：SEER数据库分析讲者：Alhareth Alhusban (约旦安曼) 摘要号：381MO 英文标题：Progression Free Survival and Overall Survival in Platinum-Based Chemotherapy Alone versus Immune Checkpoint Inhibitor (ICI)-Platinum-Based Chemotherapy Combination in First Line Treatment for Advanced, Metastatic or Recurrent Endometrial Adenocarcinoma: A Meta-Analysis 中文标题：晚期、转移性或复发性子宫内膜腺癌一线治疗中单独使用铂类化疗vs免疫检查点抑制剂(ICI)+铂类化疗的无进展生存期和总生存期：一项荟萃分析讲者：Maria Carmela Y. Vistal (菲律宾奎松城) （来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床结果抗体药物偶联物临床研究

2024-09-23

·生物探索

Cell Metab | 王菲/肖佳/王华合作揭示髓系β-arrestin 2在代谢功能障碍相关的脂肪性肝病中的作用

引言代谢功能障碍相关的脂肪性肝病（MASLD）是全球性的健康问题，影响全球约25%的人口。代谢功能障碍相关的脂肪性肝炎（MASH）是代谢功能障碍相关脂肪性肝病（MASL）的严重形式，是一个更为进展的阶段，其特点是伴有肝损伤、炎症和纤维化。先天免疫系统的失调在MASLD进展中起着关键作用。肝脏巨噬细胞是肝脏中最丰富的先天免疫细胞，包括肝驻留的库普弗细胞（KCs）和单核细胞来源的巨噬细胞（MDMs）。脂肪酸和脂质积累引起的肝细胞死亡能够促进KCs的激活和细胞因子的释放，随后招募MDMs进入肝脏。此外，活化的肝巨噬细胞可分泌细胞因子加剧肝脏炎症损伤，并能激活肝星状细胞（HSCs），进而促进纤维化和肝硬化的发生。 2024年9月20日，中山大学王菲、暨南大学肖佳、安徽医科大学王华团队合作在Cell Metabolism上发表了题为Myeloid beta-arrestin 2 depletion attenuates metabolic dysfunction-associated steatohepatitis via the metabolic reprogramming of macrophages的研究，该研究利用β-arrestin 2全身性和髓系特异性敲除小鼠，并构建高脂饮食 (HFD) 、高脂肪高胆固醇 (HFHC) 和蛋氨酸胆碱缺乏 (MCD) 三种饮食模型，揭示了髓系β-arrestin 2在MASH中作用及机制，为预防和干预MASH进展提供新的靶点和思路。本研究中，团队发现髓系特异性β-arrestin 2是维持肝巨噬细胞促炎表型并促进小鼠MASH进展的关键蛋白。肝脏中，β-arrestin 2主要在巨噬细胞中表达。MASLD中，人和小鼠肝巨噬细胞β-arrestin 2的表达会显著增加。髓系特异性β-arrestin 2的缺失能够减轻MASH小鼠的肝脏炎症和纤维化。机制上，β-arrestin 2的缺失能够促进肝脏巨噬细胞衣康酸的产生，抑制巨噬细胞M1型极化。模式图（Credit: Cell Metabolism）参考文献 https://www.cell.com/cell-metabolism/abstract/S1550-4131(24)00362-0 责编|探索君排版|探索君文章来源|“BioArt” End 往期精选围观一文读透细胞死亡(Cell Death) | 24年Cell重磅综述（长文收藏版）热文 Cell | 是什么决定了细胞的大小？热文 Nature | 2024年值得关注的七项技术热文 Nature | 自身免疫性疾病能被治愈吗？科学家们终于看到了希望热文 CRISPR技术进化史 | 24年Cell综述

2024-09-14

·精准药物

胃癌精准治疗的新策略

【导读】癌细胞自主改变代谢途径以响应微环境中动态的营养条件，以维持细胞的生存和增殖。更好地了解这些适应性改变可能揭示癌细胞的脆弱性。 9月12日，安徽医科大学郭继政研究团队在期刊《Cell Death&Disease》上发表了研究论文，题为“The NRF2-CARM1 axis links glucose sensing to transcriptional and epigenetic regulation of the pentose phosphate pathway in gastric cancer”，本研究中，研究人员证明了辅助激活因子相关精氨酸甲基转移酶1 (CARM1)在胃癌中频繁过表达，并预测胃癌患者的不良预后。胃癌细胞感知到细胞外葡萄糖含量的降低，导致NRF2的激活。随后，NRF2介导经典抗氧化途径以消除低糖诱导的活性氧簇积聚。研究人员发现NRF2与CARM1启动子结合，上调其表达，并触发高甲基化。这种脱氢酶的上调由H3R17me2修饰驱动，使葡萄糖碳通量重定向于磷酸戊糖途径。这种重定向有助于核苷酸合成和氧化还原稳态，并最终促进癌细胞的生存和生长。在低糖条件下，NRF2或CARM1敲低导致H3R17me2a降低，同时伴有葡萄糖-6-磷酸脱氢酶的降低。综上所述，本研究揭示了CARM1在调节肿瘤代谢转换中的重要作用，并确定了CARM1作为胃癌治疗的潜在治疗靶点。 https://www.nature.com/articles/s41419-024-07052-3#Sec30 背景知识 01 营养物质(尤其是葡萄糖)的供应有限，给实体肿瘤的生存带来巨大障碍，但癌细胞的重要标志——代谢重写，使其能够优化利用稀缺的营养物质。癌细胞在营养获取和利用方面的高度适应性和灵活性维持了它们在营养不良环境中的生存和生长。癌细胞的代谢依赖性不同于正常细胞，也是肿瘤细胞的"阿喀琉斯之踵"。作为肿瘤细胞代谢的重要组成部分，葡萄糖代谢为其他重要代谢途径，包括核苷酸、脂类和氨基酸的合成提供必要的中间产物和前体。磷酸戊糖途径(PPP)是一种主要的葡萄糖分解代谢途径，由氧化和非氧化分支组成。氧化支包括三个不可逆的反应，将糖酵解中间体转化，包括葡萄糖-6-磷酸(G6P)转化为核糖-5-磷酸(R5P)，并产生NADPH。NADPH提供还原性，并被用于许多合成代谢反应和抗氧化防御，这是细胞生存和生长所必需的。非氧化PPP分支包括一系列可逆性反应，这些反应调节糖酵解和PPP之间的碳通量，以满足细胞的代谢需求。越来越多的证据表明，PPP通量增强并与许多人类癌症的进展和耐药密切相关。在癌细胞中，由于不同类型的人类癌症的高度异质性，PPP活性在特定的应激条件下受到不同机制的严格控制。然而，癌细胞如何通过感知环境葡萄糖来协调葡萄糖通量仍不完全清楚。 CARM1增强低糖条件下胃癌细胞的恶性行为 02 葡萄糖饥饿诱导的CARM1表达上调提示其可能在胃癌细胞应对低糖应激中发挥重要作用。研究人员假设CARM1在低糖条件下促进细胞存活和增殖。在低糖条件下，敲低CARM1显著延迟了MGC-803和AGS细胞的增殖和克隆形成能力。流式细胞术分析显示，敲除CARM1后，G0/G1期细胞比例显著增加，S期细胞比例显著减少，表明细胞周期进程受到显著抑制。接下来，研究人员研究了CARM1是否调节核苷酸合成。在正常糖条件下，CARM1缺失对细胞上述恶性行为的影响明显弱于低糖培养。这些结果强烈表明，CARM1在营养缺乏条件下对胃癌细胞的增殖和生存起着更关键的作用，突出了其在低糖条件下的功能意义。 CARM1可增强低糖环境下胃癌细胞的恶性行为葡萄糖剥夺显著增加MGC-803和AGS细胞内ROS水平，而敲低CARM1导致胃癌细胞内ROS水平进一步增加，表明CARM1参与细胞内ROS的调控。与这些结果一致，葡萄糖剥夺降低了胃癌细胞中的GSH/GSSG比值和NADPH含量，而CARM1的缺失进一步导致GSH/GSSG比值和NADPH含量更明显的降低。葡萄糖剥夺产生的ROS与癌症细胞凋亡的诱导密切相关。在低糖条件下，与亲本细胞(CARM1野生型)相比，CARM1敲低的细胞有更高的凋亡率。研究人员进一步测定了CARM1敲低细胞在氧化应激条件下的活力。与亲本细胞相比，CARM1敲低细胞对H2O2的耐受性较低。这些数据表明，CARM1在保护癌细胞免受葡萄糖饥饿引发的凋亡和氧化损伤中是必不可少的。为了进一步评估CARM1对肿瘤生长的影响，研究人员将野生型和CARM1敲除的AGS细胞通过皮下注射的方式注射到裸鼠体内。结果显示，当这些细胞在不利的皮下环境中生长时，CARM1的缺失导致它们失去了生长优势。 G6PD 和 H3R17me2 在胃癌中上调表达 03 为了探讨研究人员发现的G6PD与H3R17甲基化相关且在葡萄糖饥饿条件下在胃癌细胞中上调的临床相关性，研究人员对人原发性胃癌组织样本中的G6PD表达和H3R17甲基化水平进行了IHC分析。IHC染色和直接免疫印迹分析显示，G6PD在胃肿瘤组织中过度表达，H3R17的甲基化水平在肿瘤组织中高于正常对照组织。这与研究所示的结果一致，NRF2的超激活、CARM1的水平、G6PD的表达和H3R17的甲基化之间存在显著且正相关的关系。总之，这些发现揭示了NRF2-CARM1轴在调控胃癌PPP方面的新作用。研究小结 04 总之，本研究表明，NRF2在葡萄糖剥夺导致的细胞内ROS水平升高的刺激下被激活。NRF2通过经典的抗氧化途径上调抗氧化基因的表达。细胞通过NRF2将ROS信号传递给CARM1，以表达葡萄糖缺乏的信号。CARM1的上调导致H3R17的超甲基化，进而上调G6PD并促进PPP活性。CARM1-依赖的PPP活性增强产生ROS清除的中间代谢产物和核酸，从而促进胃癌细胞在代谢压力下的生存和生长。这些发现对于基于CARM1的胃癌患者的精准治疗策略的发展具有重要意义。【参考资料】 https://www.nature.com/articles/s41419-024-07052-3#Sec30 声明：发表/转载本文仅仅是出于传播信息的需要，并不意味着代表本公众号观点或证实其内容的真实性。据此内容作出的任何判断，后果自负。若有侵权，告知必删！长按关注本公众号粉丝群/投稿/授权/广告等请联系公众号助手觉得本文好看，请点这里↓

细胞疗法免疫疗法寡核苷酸核酸药物

100 项与安徽医科大学相关的药物交易

登录后查看更多信息

100 项与安徽医科大学相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年12月23日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Cpd-564 ( METTL3 )	急性肾损伤更多	临床前
SF38 ( DPP-1 )	炎症更多	临床前
Inflammation-compound 22(Anhui Medical University)	炎症更多	临床前
BF02(Anhui Medical University) ( TNFR2 )	类风湿关节炎更多	临床前
CP-25 ( A1R )	干燥综合征更多	临床前